scholarly journals Reversible alteration of Nerve Conduction Velocity in Iron Deficient Anemic Patients in Response to Treatment

2021 ◽  
pp. 40-44
Author(s):  
G. Sharma ◽  
S. Gupta ◽  
S. K. Atri ◽  
P. Sharma
Keyword(s):  
Nervous System ◽  
Iron Deficiency ◽  
Replacement Therapy ◽  
Peripheral Nervous System ◽  
Iron Deficiency Anemia ◽  
Nerve Conduction ◽  
Nerve Fibers ◽  
Response To Treatment ◽  
Deficiency Anemia ◽  
Iron Replacement

Aim: Evaluation of nerve conduction in adult patients of iron deficiency anemia and to study the response to treatment. Study Design: Prospective randomized control study Place and Duration of Study: Department of Medicine and Department of Physiology, PGIMS Rohtak Introduction: Iron deficiency anemia is associated with central and peripheral nervous system disturbances. Iron is an essential component of brain growth, myelination, nerve impulse conduction, protein synthesis, hormone production, fundamental aspects of cellular energy metabolism and is involved in neurotransmitter synthesis including serotonin, norepinephrine and dopamine. Hence, its deficiency adversely affects motor performance, mental development as well as cognitive and behavioral functions. Since myelination is concerned with conduction in nerve fibers, iron deficiency potentially impairs neuronal transmission and leads to functional neurodeficit like dysfunction in the peripheral nervous system such as paresthetic complaints. Method: Nerve conduction was recorded using RMS EMG EP MK2 machine in 30 newly diagnosed patients of iron deficiency anemia with haemoglobin less than 10.9-4 g/dl between 18-50 years of age who were followed up after 3 months of treatment and compared with 30 age and sex matched controls. Results: An increase in distal latencies and a decrease in amplitude and nerve conduction velocities of motor and sensory component of all the nerves was seen in IDA patients as compared to the control groups which was reversible with iron replacement therapy. Conclusion: Altered values of nerve conduction parameters indicates peripheral neuropathy in IDA individuals with or without polyneuropathy. Thus, nerve conduction study provides an objective method for monitoring the function of PNS, especially the clinically silent peripheral nerve compromise in patients of iron deficiency anemia before and after iron replacement therapy.  Thus NCS is a non-invasive test for early diagnosis and therefore early treatment to prevent complications.

scholarly journals Reversible alteration of brainstem auditory evoked potential in iron deficient anemic patients in response to treatment

2021 ◽  
Vol 8 (4) ◽  
pp. 1877
Author(s):  
Sushant Gupta ◽  
Geetanjali Sharma ◽  
Sudhir K. Atri ◽  
Priyanka Sharma
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Electrophysiological Study ◽  
Nerve Fibers ◽  
Auditory Evoked Potential ◽  
Response To Treatment ◽  
Deficiency Anemia ◽  
Hormone Production ◽  
Iron Deficient ◽  
Iron Replacement

Background: Iron deficiency anemia is associated with central and peripheral nervous system disturbances. Iron is an essential component of brain growth, myelination, nerve impulse conduction, protein synthesis, hormone production, fundamental aspects of cellular energy metabolism and is involved in neurotransmitter synthesis including serotonin, norepinephrine and dopamine. Hence, its deficiency adversely affects motor performance, mental development as well as cognitive and behavioral functions. Since myelination is concerned with conduction in nerve fibers, iron deficiency potentially impairs neuronal transmission and leads to functional neurodeficit like hearing loss.Methods: BAEP was recorded using RMS EMG EP MK2 machine in patients of iron deficiency anemia with haemoglobin less than 10.9 g/dl between 18-50 years of age who were followed up after 3 months of treatment and compared with 30 age and sex matched controls.Results: BAEP absolute and interpeak latencies were prolonged in IDA patients as compared to the control groups which was reversible with iron replacement therapy.Conclusions: Increased absolute and interpeak latencies of BAEP indicates impairment of auditory pathways in IDA patients. Thus, the electrophysiological study of BAEP provides an objective method for monitoring the function of CNS, especially the auditory function in iron deficiency anemia patients before and after iron replacement therapy. It is a non-invasive test for early diagnosis and therefore early treatment to prevent complications. 

scholarly journals Oral Iron Therapy-Induced Neutropenia in Patient with Iron Deficiency Anemia

2020 ◽  
Vol 13 (2) ◽  
pp. 721-724 ◽  
Author(s):  
Mohammad N. Kloub ◽  
Mohamed A. Yassin
Keyword(s):  
Iron Deficiency ◽  
Replacement Therapy ◽  
Iron Deficiency Anemia ◽  
Male Patient ◽  
Hematological Parameters ◽  
Oral Iron ◽  
Iron Therapy ◽  
Deficiency Anemia ◽  
Oral Iron Therapy ◽  
Iron Replacement

Iron deficiency anemia is common and worldwide distributed, particularly among females; however, it can also occur among males. Iron deficiency anemia is commonly associated with thrombocytosis; little is known about the effect of iron therapy (oral or intravenous) on other hematological parameters. We report a 29-year-old male patient with iron deficiency anemia, who received oral iron replacement therapy and developed neutropenia which recovered spontaneously 1 month later.

scholarly journals Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion

2021 ◽  
Vol 10 (19) ◽  
pp. 4448
Author(s):  
Carsten Schmidt ◽  
Stephen Allen ◽  
Nelson Kopyt ◽  
Pablo Pergola
Keyword(s):  
Iron Deficiency ◽  
Replacement Therapy ◽  
Iron Deficiency Anemia ◽  
Transferrin Saturation ◽  
The United States ◽  
Deficiency Anemia ◽  
Published Evidence ◽  
Long Term Treatment ◽  
Iron Replacement

Iron deficiency is the most common cause of anemia globally and is frequently reported in patients with underlying inflammatory conditions, such as inflammatory bowel disease (IBD) and chronic kidney disease (CKD). Ferric maltol is a new oral iron replacement therapy designed to optimize iron absorption while reducing the gastrointestinal adverse events associated with unabsorbed free iron. Ferric maltol has been studied in clinical trials involving almost 750 adults and adolescents with iron-deficiency anemia associated with IBD, CKD, and other underlying conditions, and it has been widely used in clinical practice. It is approved for the treatment of adults with iron deficiency with or without anemia, independent of the underlying condition, and is commercially available in Europe and the United States. We review the published evidence for ferric maltol, which demonstrates consistent and clinically meaningful improvements in hemoglobin and measures of iron availability (ferritin and transferrin saturation) and shows that it is well-tolerated over long-term treatment for up to 64 weeks—an important consideration in patients with chronic underlying conditions such as IBD and CKD. We believe that ferric maltol is an effective, convenient, and well-tolerated treatment option for iron deficiency and iron-deficiency anemia, especially when long-term management of chronic iron deficiency is required. Writing support was provided by Shield Therapeutics (Gateshead, UK).

Effect of Omeprazole on Oral Iron Replacement in Patients with Iron Deficiency Anemia

2004 ◽  
Vol 97 (9) ◽  
pp. 887-889 ◽  
Author(s):  
Vivek R. Sharma ◽  
Mark A. Brannon ◽  
Elizabeth A. Carloss
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Oral Iron ◽  
Deficiency Anemia ◽  
Iron Replacement
Sign in / Sign up

Export Citation Format

Share Document